Does pemetinib/pemetinib need to be taken for a long time and can it be stopped?

Pemigatinib is an anti-cancer drug that targets FGFR gene abnormalities. It is mainly suitable for the treatment of patients with locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 fusion or rearrangement, as well as some patients with hematological tumors carrying FGFR1 rearrangement. During the treatment process, whether long-term use is required and whether the drug can be discontinued must be comprehensively judged based on the patient's specific condition, treatment response, and side effects. For patients with cholangiocarcinoma, an intermittent treatment regimen is usually adopted, that is, 13.5 mg once a day, taking the drug for 14 days, and then stopping the drug for 7 days, forming a 21-day cycle. This method helps to reduce the toxic burden of the drug. For patients with certain hematological diseases, such as myeloid or lymphoid tumors with FGFR1 rearrangements, they may need to continue taking it daily until the disease progresses or they are intolerable.

Whether you can stop taking your medication depends on a variety of factors. If the patient achieves complete remission during treatment, the doctor may evaluate whether the medication can be discontinued, but in most cases, as long as the disease has not progressed and the patient can tolerate the side effects, it is recommended to continue taking the medication to maintain the effect. Discontinuation of the drug usually requires careful decision-making, especially when the tumor burden is still there or the disease has a high risk of recurrence. Hasty discontinuation may lead to a rapid rebound of the disease. In addition, long-term use of pemetinib requires regular monitoring of blood phosphorus levels, liver and kidney function, vision and other indicators, because common adverse reactions of this drug include hyperphosphatemia, eye discomfort, alopecia, oral mucositis, etc. If not managed in time, it may affect the continuity of long-term treatment and the patient's quality of life.

In short, whether pemetinib needs to be taken for a long time or whether it can be discontinued is not a fixed answer. It needs to be judged based on the molecular characteristics of the tumor, treatment stage, tolerance, and imaging and laboratory evaluation results. Patients should not stop taking the medicine on their own, but should dynamically adjust the treatment plan according to the efficacy and side effects under the guidance of a doctor to ensure maximum efficacy and reduce the risk of adverse reactions.

Reference materials:https://go.drugbank.com/drugs/DB15102